Сравнение результатов теста AUDIT и лабораторного контроля фосфатидилэтанола в крови с целью определения характера потребления алкоголя у пациентов с циррозом печени алкогольной этиологии

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Иконникова К.А., Ерощенко Н.Н., Клименко Т.В., Дроздов В.Н., Ших Е.В. Сравнение результатов теста AUDIT и лабораторного контроля фосфатидилэтанола в крови с целью определения характера потребления алкоголя у пациентов с циррозом печени алкогольной этиологии // Российский психиатрический журнал. 2022. №1. С. 73-80.

Аннотация

Проведено когортное обсервационное исследование с целью сопоставления характера употребления алкоголя по результатам AUDIT (Alcohol Use Disorders Inventory Test) с содержанием в крови биомаркера алкоголя фосфатидилэтанола (ФЭ) у мужчин старше 18 лет (n=112) с алкогольным поражением печени в анамнезе. Расстройство употребления алкоголя по результатам AUDIT (≥8 баллов) обнаружено у 52 (46,4%) пациентов, при этом ФЭ в крови выявлен у 74 человек (66%). В группе с 0–7 баллов по AUDIT ФЭ обнаружен в 36,6% случаев, в группе с 16–19 баллами – в 100%. В группе с ≥20 баллов по AUDIT маркер обнаружен у 5 из 8 пациентов (62,5%) в диапазоне концентраций 61,2–251,1 нг/мл, следовательно, в этой группе оказались пациенты с разным характером потребления, что характерно и для других групп. Не отмечено взаимосвязи между уровнем ФЭ и результатами AUDIT. Пациенты испытывали трудность с заполнением вопросника, поэтому целесообразно включать лабораторную диагностику ФЭ в обследование пациентов с подозрением на чрезмерное потребление алкоголя.

Ключевые слова Alcohol Use Disorders Inventory Test (AUDIT); фосфатидилэтанол; биомаркеры употребления алкоголя

Литература

1. World Health Organization. Global status report on alcohol and health 2018. 450 p. 2. Parry CD, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction. 2011;106(10):1718–24. DOI: https://doi.org/10.1111/j.1360-0443.2011.03605.x 3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology. 2018;69(1):154–81. DOI: https://doi.org/10.1016/j.jhep.2018.03.018 4. Ivashkin VT, Maevskaya MV, Pavlov ChS, et al. [Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2017;27(6):20–40. (In Russ.) DOI: https://doi.org/10.22416/1382-4376-2017-27-6-20-40 5. Sepanlou SG, Safiri S, Bisignano C, Ikuta, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(3):245–66. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8 6. Gofman AG, Ponizovskii PA. [Comorbidity of mental desorders with alcohol addiction]. Voprosy narkologii. 2018;2:102–13. (In Russ.) 7. Lai HMX, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug and Alcohol Dependence. 2015;154:1–13. DOI: https://doi.org/10.1016/j.drugalcdep.2015.05.031 8. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test. 2001. 37 р. 9. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. 1993;88(6):791–804. DOI: https://doi.org/10.1111/j.1360-0443.1993.tb02093.x 10. Lange S, Shield K, Monteiro M, Rehm J. Facilitating Screening and Brief Interventions in Primary Care: A Systematic Review and Meta‐Analysis of the AUDIT as an Indicator of Alcohol Use Disorders // Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2019;43(10):2028–37. DOI: https://doi.org/10.1111/acer.14171 11. Aradottir S, Asanovska G, Gjerss S, et al. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol and Alcoholism. 2006;41(4):431–7. DOI: https://doi.org/10.1093/alcalc/agl027 12. Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarkerс–comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addiction Biology. 2007;12(1):81–4. DOI: https://doi.org/10.1111/j.1369-1600.2006.00040.x 13. Kummer N, Ingels AS, Wille SM, et al. Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol withdrawal and control volunteers. Analytical and Bioanalytical Chemistry. 2016;408(3):825–38. DOI: https://doi.org/10.1007/s00216-015-9169-1 14. Gnann H, Weinmann W, Thierauf A. Formation of Phosphatidylethanol and Its Subsequent Elimination During an Extensive Drinking Experiment Over 5 Days. Alcoholism: Clinical and Experimental Research. 2012;36(9):1507–11. DOI: https://doi.org/10.1111/j.1530-0277.2012.01768.x 15. Dasgupta A. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Elsevier Inc., 2015. 300 p. 16. Stewart SH, Koch DG, Willner IR, et al. Validation of Blood Phosphatidylethanol as an Alcohol Consumption Biomarker in Patients with Chronic Liver Disease. Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2014;38(6):1706–11. DOI: https://doi.org/10.1111/acer.12442 17. Andresen‐Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transplant International. Blackwell Publishing Ltd. 2017;30(6):611–20. DOI: https://doi.org/10.1111/tri.12949 18. Helander A, Böttcher M, Dahmen N, et al. Elimination Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Blood during Alcohol Detoxification. Alcohol and Alcoholism. 2019;54(3):251–7. DOI: https://doi.org/10.1093/alcalc/agz027 19. Helander A, Hermansson U, Beck O. Dose–Response Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) – A Study of Outpatients in Treatment for Reduced Drinking. Alcohol and Alcoholism. 2019;54(6):567–73. DOI: https://doi.org/10.1093/alcalc/agz064 20. Walther L, de Bejczy A, Löf E, et al. Phosphatidylethanol is Superior to Carbohydrate-Deficient Transferrin and γ -Glutamyltransferase as an Alcohol Marker and is a Reliable Estimate of Alcohol Consumption Level. Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2015;39(11):2200–8. DOI: https://doi.org/10.1111/acer.12883 21. Viel G, Boscolo-Berto R, Cecchetto G, et al. Phosphatidylethanol in Blood as a Marker of Chronic Alcohol Use: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2012;13(12):14788–812. DOI: https://doi.org/10.3390/ijms131114788 22. Simon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regulatory Toxicology and Pharmacology. 2018;94:163–71. DOI: https://doi.org/10.1016/j.yrtph.2018.01.029 23. World Health Organization. International guide for monitoring alcohol consumption and related harm. WHO/MSD/MSB/00.4. 2000. 193 p. 24. Helander A, Zheng Y. Molecular Species of the Alcohol Biomarker Phosphatidylethanol in Human Blood Measured by LC-MS. Clinical Chemistry. 2009;55(7):1395–405. DOI: https://doi.org/10.1373/clinchem.2008.120923 25. Babor TF, Robaina K. The Alcohol Use Disorders Identification Test (AUDIT): A review of graded severity algorithms and national adaptations. The International Journal of Alcohol and Drug Research. 2016;5(2):17–24. DOI: https://doi.org/10.7895/ijadr.v5i2.222 26. Pavlov AI. [Alcoholic liver disease: diagnosis and management in general hospital]. Effektivnaya farmakoterapiya. 2013;41:30–7. (In Russ.)



DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10109

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM